Dew wrote a post about NVO's CKD trial with Ozempic . You responded by lumping this trial and its potential impact on those with CKD ...with your over all view on how Ozempic is being used . Perhaps you could address the intro of Dew's piece ...the affect on dialysis and med tech stocks....because for those in stage 4 CKD, this trials results may have a significant impact on their life expectancy and their need for dialysis ( and by extension on the companies that sell meds or med tech for this population ) We don't know how much Ozempic slows decline in eGFR ( kidney function ) yet in this population . But since the trial was stopped 1 yr early for efficacy I'll assume if must be significant . Kiwi
There’s a serious issue here hiding behind the comicality. The dude in your photo might lose 75 pounds on Ozempic or Mounjaro and still not improve his mile time significantly, or at all. That’s because these drugs (Mounjaro more so than Ozempic) cause loss of lean muscle mass as well as fat.
Market Data 
Markets 
AI
